Inhibrx Biosciences, Inc. Common Stock INBX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T15:44:50.168Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:37:44.473498459Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T15:44:49.759508+00:00
Inhibrx Biosciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 190.08 | 404.4% | 116.9% | 69.43 | 255.2% | 28.3% |
| 25Δ | 136.69 | 290.3% | 57.6% | 76.30 | 199.7% | 20.7% |
| 30Δ | 114.68 | 218.3% | 33.1% | 81.13 | 162.2% | 15.3% |
| 35Δ | 104.21 | 177.3% | 21.6% | 84.75 | 135.8% | 11.4% |
| 40Δ | 98.56 | 152.6% | 15.6% | 87.03 | 121.7% | 9.2% |
| 45Δ | 94.51 | 135.8% | 11.6% | 89.21 | 108.6% | 7.1% |
| 50Δ | 92.18 | 143.4% | 10.5% | 91.16 | 102.8% | 5.8% |
| 55Δ | 89.84 | 150.0% | 9.4% | 92.96 | 101.2% | 4.9% |
| 60Δ | 87.35 | 141.0% | 7.5% | 94.77 | 99.6% | 4.0% |
| 65Δ | 84.90 | 132.0% | 5.6% | 96.64 | 97.6% | 3.3% |
| 70Δ | 83.03 | 122.9% | 4.4% | 98.51 | 95.5% | 2.6% |
| 75Δ | 81.17 | 113.9% | 3.2% | |||
| 80Δ | 78.97 | 108.7% | 2.2% | 106.53 | 114.6% | 1.8% |
20Δ
- Pseudo strike
- 190.08
- IV
- 404.4%
- B/E move
- 116.9%
- Pseudo strike
- 69.43
- IV
- 255.2%
- B/E move
- 28.3%
25Δ
- Pseudo strike
- 136.69
- IV
- 290.3%
- B/E move
- 57.6%
- Pseudo strike
- 76.30
- IV
- 199.7%
- B/E move
- 20.7%
30Δ
- Pseudo strike
- 114.68
- IV
- 218.3%
- B/E move
- 33.1%
- Pseudo strike
- 81.13
- IV
- 162.2%
- B/E move
- 15.3%
35Δ
- Pseudo strike
- 104.21
- IV
- 177.3%
- B/E move
- 21.6%
- Pseudo strike
- 84.75
- IV
- 135.8%
- B/E move
- 11.4%
40Δ
- Pseudo strike
- 98.56
- IV
- 152.6%
- B/E move
- 15.6%
- Pseudo strike
- 87.03
- IV
- 121.7%
- B/E move
- 9.2%
45Δ
- Pseudo strike
- 94.51
- IV
- 135.8%
- B/E move
- 11.6%
- Pseudo strike
- 89.21
- IV
- 108.6%
- B/E move
- 7.1%
50Δ
- Pseudo strike
- 92.18
- IV
- 143.4%
- B/E move
- 10.5%
- Pseudo strike
- 91.16
- IV
- 102.8%
- B/E move
- 5.8%
55Δ
- Pseudo strike
- 89.84
- IV
- 150.0%
- B/E move
- 9.4%
- Pseudo strike
- 92.96
- IV
- 101.2%
- B/E move
- 4.9%
60Δ
- Pseudo strike
- 87.35
- IV
- 141.0%
- B/E move
- 7.5%
- Pseudo strike
- 94.77
- IV
- 99.6%
- B/E move
- 4.0%
65Δ
- Pseudo strike
- 84.90
- IV
- 132.0%
- B/E move
- 5.6%
- Pseudo strike
- 96.64
- IV
- 97.6%
- B/E move
- 3.3%
70Δ
- Pseudo strike
- 83.03
- IV
- 122.9%
- B/E move
- 4.4%
- Pseudo strike
- 98.51
- IV
- 95.5%
- B/E move
- 2.6%
75Δ
- Pseudo strike
- 81.17
- IV
- 113.9%
- B/E move
- 3.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 78.97
- IV
- 108.7%
- B/E move
- 2.2%
- Pseudo strike
- 106.53
- IV
- 114.6%
- B/E move
- 1.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 104.09% | |
| 108.62% | |
| 113.21% | |
| 112.24% | |
| 121.88% | |
| 122.41% | |
| 107.39% | |
| 108.26% | |
| 109.79% | |
| 109.93% | |
| 110.63% | |
| 114.34% | |
| 116.38% | |
| 118.54% | |
| 120.50% | |
| 121.18% | |
| 121.50% | |
| 93.95% | |
| 87.81% | |
| 90.11% | |
| 89.69% | |
| 94.48% | |
| 99.42% | |
| 114.22% | |
| 108.75% | |
| 85.64% | |
| 84.99% | |
| 85.30% | |
| 84.94% | |
| 85.82% | |
| 86.38% | |
| 87.34% | |
| 86.49% | |
| 88.27% | |
| 86.75% | |
| 85.10% | |
| 86.93% | |
| 86.98% | |
| 81.17% | |
| 84.35% | |
| 88.69% | |
| 95.69% | |
| 109.57% | |
| 118.37% | |
| 127.22% | |
| 85.47% | |
| 88.50% | |
| 86.74% | |
| 87.40% | |
| 88.21% | |
| 91.09% | |
| 89.90% | |
| 88.57% | |
| 95.94% | |
| 91.13% | |
| 91.39% |
Biotechnology
INCY
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
More →INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic…
More →INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases…
More →INSM
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New…
More →INVA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
More →IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
More →